Various clinical observations have implicated T cells in the control of chronic myeloid leukemia (CML). These observations have in recent years been supported by laboratory results indicating the presence of CML‐specific T cells in the lymphocyte repertoire of both normal healthy individuals and disease‐bearing patients. Both MHC‐unrestricted and MHC‐restricted immune effector mechanisms are involved. Donor lymphocyte infusion has produced encouraging GvL effects. However, future adoptive immunotherapy may depend on the isolation and generation of leukemia‐specific T cells. Although many proteins may potentially act as leukemia antigens in CML for MHC‐restricted cytotoxicity, the bcr‐abl fusion protein has been most extensively investigated. There is now much evidence to suggest that the bcr‐abl junctional peptides are capable of eliciting both CD4 and CD8 responses in normal healthy donors and CML patients. Furthermore, the T‐cell lines generated react with autologous or HLA‐matched fresh CML cells, suggesting that the bcr‐abl fusion protein can be processed in vivo so that the joining segment is bound to HLA molecules in a configuration and concentration similar to those of the immunizing peptide for antigen recognition by the antigen‐specific T‐cell receptor. These results also indicate that the bcr‐abl junctional peptides may be used for immunotherapy of CML. Other strategies available for immunotherapy of CML include immunologically or genetically manipulated donor T‐cell infusion, the use of cytokines, adoptive immunotherapy with leukemia‐reactive T‐cells expanded ex vivo, and immune gene therapy. Novel and rational immunotherapy may therefore play an important adjuvant role in future in the management of patients with CML. Am. J. Hematol. 54:61–67, 1997 © Wiley‐Liss, Inc.